Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7018 in Relapsed or Refractory Non-Hodgkin Lymphoma
NCT06622226Phase 1Terminated
- Sponsor
- Ono Pharmaceutical
- Start
- Nov 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ONO-7018 in non-Hodgkin lymphoma (NHL), sponsored by Ono Pharmaceutical. Primary endpoints: Dose-limiting toxicities at 3 weeks and Treatment emergent adverse events and Treatment-Emergent Serious Adverse Events at 28 days. Started Nov 2024; status: terminated.
02
Drugs
ONO-7018
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06622226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06622226.